4.8 Article

A chemoselective strategy for late-stage functionalization of complex small molecules with polypeptides and proteins

期刊

NATURE CHEMISTRY
卷 11, 期 1, 页码 78-85

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41557-018-0154-0

关键词

-

资金

  1. NIH [GM46059, F32GM108294, F32GM122204, F30HD093358, GM110535]
  2. MIT startup funds
  3. Damon Runyon Cancer Research Foundation Award
  4. Sontag Distinguished Scientist Award
  5. George Buchi Summer Research Fellowship
  6. Koch Graduate Fellowship in Cancer Research
  7. Bristol-Myers Squibb Fellowship in Synthetic Organic Chemistry
  8. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [F30HD093358] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM122204, R37GM068649, R01GM046059, R35GM122483, R01GM110535] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Conjugates between proteins and small molecules enable access to a vast chemical space that is not achievable with either type of molecule alone; however, the paucity of specific reactions capable of functionalizing proteins and natural products presents a formidable challenge for preparing conjugates. Here we report a strategy for conjugating electron-rich (hetero) arenes to polypeptides and proteins. Our bioconjugation technique exploits the electrophilic reactivity of an oxidized selenocysteine residue in polypeptides and proteins, and the electron-rich character of certain small molecules to provide bioconjugates in excellent yields under mild conditions. This conjugation chemistry enabled the synthesis of peptide-vancomycin conjugates without the prefunctionalization of vancomycin. These conjugates have an enhanced in vitro potency for resistant Gram-positive and Gram-negative pathogens. Additionally, we show that a 6 kDa affibody protein and a 150 kDa immunoglobulin-G antibody could be modified without diminishing bioactivity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据